Conditional PD-1/PD-L1 Probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti–PD 1/PD-L1 agents
Assi HH, Wong C, Tipton KA, et.al. Cancer Immunol Res. October 11 2021. DOI: 10.1158/2326-6066.CIR-21-0031